A new study on Eriomin, a blend of citrus flavonoids marketed by Ingredients By Nature, revealed an association between the ingredient and positive changes within the gut microbiota of prediabetic participants.
 
The research, published in Food Science & Nutrition, demonstrated that the ingredient, which primarily features a flavonoid called eriocitrin, has the potential to attenuate intestinal dysbiosis.
 
In the 12-week, double-blind, randomized controlled clinical trial, 29 participants between the ages of 30 and 69 completed a protocol in which they took 200 mg of Eriomin or a placebo daily, while maintaining their usual diet. Two registered dietitians followed study participants during the trial period, and blood and fecal samples were collected at baseline and the end of the study.
 
By the end of the treatment, researchers found that Eriomin supplementation was linked to significant reductions of Firmicutes, a phylum of bacteria found in high levels in prediabetic and obese individuals and associated with a carbohydrate-rich diet. Eriomin also decreased abundance of the Lachnospiraceae family, which is linked to glycemic dysregulation, metabolic syndrome, excess weight, and prediabetes.
 
In contrast, the Ruminococcaceae family increased by 38% with Eriomin supplementation, while it decreased in the placebo group. This family of bacteria produces short-chain fatty acids, which can improve intestinal barrier function and support a healthy inflammatory response.
 
There was also a decrease in the genus Blautia, which has been linked to the weakening of the intestinal walls in other studies. In the present study, a positive correlation was found between Blautia and hyperglycemia, suggesting that Blautia depletion was associated with reduced blood glucose in the patients treated with Eriomin.
 
Eriomin supplementation was also linked to a reduction in fasting glucose by 6.5%, and increased GLP-1 incretin by 22%, which was statistically significantly different from the placebo group.
 
“These results further demonstrate Eriomin’s potential for those who need support in maintaining healthy blood glucose levels,” said Rob Brewster, president of Ingredients by Nature. “This is the third published human clinical trial backing Eriomin. We are thrilled to share this news with the industry and will continue investigating Eriomin’s powerful effects for numerous health benefits.”